The study compared standard chemotherapy alone, which consisted of a combination of capecitabine or fluorouracil (5-FU) with cisplatin, with chemotherapy combined with trastuzumab for primary treatment of HER2-positive advanced gastric cancer and oesophagogastric junction cancer. The gene discussed is ERBB2; the disease is gastric cancer.